Company Description
Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings.
The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics.
It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies.
Baudax Bio, Inc. was incorporated in 2019 and is based in Malvern, Pennsylvania. On February 22, 2024, Baudax Bio, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Eastern District of Pennsylvania.
Contact Details
Address: 490 Lapp Road Malvern, Pennsylvania 19355 United States | |
| Phone | 484-395-2470 |
Stock Details
| Ticker Symbol | BXRXQ |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001780097 |
| Employer ID | 47-4639500 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Geraldine A. Henwood Ph.D. | President, Chief Executive Officer and Director |
| Mike Choi | Vice President of Financial Planning and Analysis |
| Natalie McAndrew | Consultant and Principle Accounting Officer |
| Dr. Chan Kim Yong Ph.D. | Chief Scientific Officer and Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 28, 2024 | 8-K | Current Report |
| Feb 15, 2024 | 25-NSE | Filing |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 6, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Dec 13, 2023 | 8-K | Current Report |
| Nov 22, 2023 | 424B3 | Prospectus |
| Nov 20, 2023 | 10-Q | Quarterly Report |
| Nov 15, 2023 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| Nov 15, 2023 | 8-K | Current Report |
| Oct 25, 2023 | 8-K | Current Report |